The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.

Constitutive expression of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) is characteristic of malignant ovarian surface epithelium. We investigated the hypothesis that this autocrine action of TNF-alpha generates and sustains a network of other mediators that promote peritoneal cancer growth and spread. When compared with two ovarian cancer cell lines that did not make TNF-alpha, constitutive production of TNF-alpha was associated with greater release of the chemokines CCL2 and CXCL12, the cytokines interleukin-6 (IL-6) and macrophage migration-inhibitory factor (MIF), and the angiogenic factor vascular endothelial growth factor (VEGF). TNF-alpha production was associated also with increased peritoneal dissemination when the ovarian cancer cells were xenografted. We next used RNA interference to generate stable knockdown of TNF-alpha in ovarian cancer cells. Production of CCL2, CXCL12, VEGF, IL-6, and MIF was decreased significantly in these cells compared with wild-type or mock-transfected cells, but in vitro growth rates were unaltered. Tumor growth and dissemination in vivo were significantly reduced when stable knockdown of TNF-alpha was achieved. Tumors derived from TNF-alpha knockdown cells were noninvasive and well circumscribed and showed high levels of apoptosis, even in the smallest deposits. This was reflected in reduced vascularization of TNF-alpha knockdown tumors. Furthermore, culture supernatants from such cells failed to stimulate endothelial cell growth in vitro. We conclude that autocrine production of TNF-alpha by ovarian cancer cells stimulates a constitutive network of other cytokines, angiogenic factors, and chemokines that may act in an autocrine/paracrine manner to promote colonization of the peritoneum and neovascularization of developing tumor deposits.

[1]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[2]  T. Hagemann,et al.  Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK1 , 2005, The Journal of Immunology.

[3]  Fan Zhang,et al.  Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes , 2006, Nature Medicine.

[4]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. , 2005, Cancer research.

[5]  Li Yan,et al.  Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. , 2006, European journal of cancer.

[6]  P. Allavena,et al.  Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. , 2004, European journal of cancer.

[7]  P. Szlosarek,et al.  Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .

[8]  P. Szlosarek,et al.  Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. , 2003, The Lancet. Oncology.

[9]  P. Szlosarek,et al.  Expression and regulation of tumor necrosis factor α in normal and malignant ovarian epithelium , 2006, Molecular Cancer Therapeutics.

[10]  A. Harris,et al.  A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[11]  Robert J. Moore,et al.  Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. , 2002, Oncogene.

[12]  P. Szlosarek,et al.  Tumour necrosis factor-α as a tumour promoter , 2006 .

[13]  S. Mok,et al.  Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. , 2002, Journal of the National Cancer Institute.

[14]  G. Stamp,et al.  The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. , 1995, The Journal of clinical investigation.

[15]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[16]  L. Karabon,et al.  IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity , 2000, British Journal of Cancer.

[17]  D. Hicklin,et al.  Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice , 2004, Cancer Research.

[18]  G. Jayson,et al.  Regulation of Fibroblast Growth Factor-2 Activity by Human Ovarian Cancer Tumor Endothelium , 2005, Clinical Cancer Research.

[19]  S. Biesterfeld,et al.  Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up , 2005, International Journal of Gynecologic Cancer.

[20]  Lieve Moons,et al.  CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.

[21]  D. Lauffenburger,et al.  The Response of Human Epithelial Cells to TNF Involves an Inducible Autocrine Cascade , 2006, Cell.

[22]  W. Fiers,et al.  Paradoxical effects of tumour necrosis factor in experimental ovarian cancer , 1989, International journal of cancer.

[23]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[24]  P. Neven,et al.  Prophylactic salpingo-oophorectomy in 51 women with familial breast–ovarian cancer: importance of fallopian tube dysplasia , 2005, International Journal of Gynecologic Cancer.

[25]  F. Balkwill,et al.  Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours , 2001, British Journal of Cancer.

[26]  W. Foulkes,et al.  Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. , 1993, The Journal of clinical investigation.

[27]  J. da Silva,et al.  Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.

[28]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[29]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[30]  D. Phillips,et al.  Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway , 2002, Oncogene.

[31]  M. Gorospe,et al.  von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA Arrays , 2003, Molecular and Cellular Biology.

[32]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.